Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | PHASE1 | COMPLETED | 80 | — | — | Jan 1, 2008 | Dec 1, 2013 | Aug 16, 2021 | 11 | United States |
| Arm | Type | Description |
|---|---|---|
| multiple dose levels | EXPERIMENTAL | 1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine. |
| Name | Type | Description |
|---|---|---|
| IMMU-107 (hPAM4) | BIOLOGICAL | 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks |
Inclusion Criteria: * Male or female patients, \>18 years of age, who are able to understand and give written informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Stage III (locally advanced, unresectable) or Stage IV (metastatic) disease, including patients wh...